Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Fresenius Medical Care AG & Co. KGaA    FME   DE0005785802

FRESENIUS MEDICAL CARE AG & CO. KGAA

(FME)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Fresenius Medical Care AG & Co. KGaA: Publication of acquisition or disposal in respect of own shares according Sec. 40 para. 1 sent. 2 WpHG

share with twitter share with LinkedIn share with facebook
03/30/2020 | 09:30am EDT

DGAP Voting Rights Announcement: Fresenius Medical Care AG & Co. KGaA
Fresenius Medical Care AG & Co. KGaA: Publication of acquisition or disposal in respect of own shares according Sec. 40 para. 1 sent. 2 WpHG

30.03.2020 / 14:24
Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Publication of acquisition or disposal in respect of own shares

1. Details of issuer
Fresenius Medical Care AG & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg
Germany

2. Names of subsidiary undertakings or third persons
holding directly 3% or more shares, if different from 1.
 

3. Date on which threshold was crossed or reached
26 March 2020 

4. Share-position
  Share-position in % total amount of shares issued
Resulting situation 3.029 % 304,444,441
Previous publication N/A % /

5. Details
absolute in %
direct indirect (via subsidiary
or third person, Sec. 71d
para. 1 AktG)
direct indirect (via subsidiary
or third person, Sec. 71d
para. 1 AktG)
9,222,164 N/A 3.029 % N/A %



30.03.2020 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Fresenius Medical Care AG & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
Internet: www.freseniusmedicalcare.com

 
End of News DGAP News Service

1010193  30.03.2020 

fncls.ssp?fn=show_t_gif&application_id=1010193&application_name=news&site_id=zonebourse
© EQS 2020

share with twitter share with LinkedIn share with facebook
All news about FRESENIUS MEDICAL CARE AG & CO. KGAA
10/26FMC FRESENIUS MEDICAL CARE AG & CO K : JP Morgan gives a Buy rating
MD
10/26FRESENIUS SE : Buy rating from JP Morgan
MD
10/26FMC FRESENIUS MEDICAL CARE AG & CO K : Receives a Buy rating from Goldman Sachs
MD
10/26FMC FRESENIUS MEDICAL CARE AG & CO K : Berenberg gives a Buy rating
MD
10/23FRESENIUS SE : Receives a Buy rating from Goldman Sachs
MD
10/23FMC FRESENIUS MEDICAL CARE AG & CO K : Gets a Buy rating from Goldman Sachs
MD
10/22FRESENIUS SE : Credit Suisse reiterates its Neutral rating
MD
10/22FMC FRESENIUS MEDICAL CARE AG & CO K : Credit Suisse reaffirms its Neutral ratin..
MD
10/22FMC FRESENIUS MEDICAL CARE AG & CO K : Credit Suisse remains Neutral
MD
10/21FRESENIUS SE : Berenberg reiterates its Buy rating
MD
More news
Financials (USD)
Sales 2020 21 511 M - -
Net income 2020 1 549 M - -
Net Debt 2020 14 311 M - -
P/E ratio 2020 15,4x
Yield 2020 1,74%
Capitalization 23 799 M 23 904 M -
EV / Sales 2020 1,77x
EV / Sales 2021 1,65x
Nbr of Employees 124 736
Free-Float 65,1%
Chart FRESENIUS MEDICAL CARE AG & CO. KGAA
Duration : Period :
Fresenius Medical Care AG & Co. KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FRESENIUS MEDICAL CARE AG & CO. KGAA
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 97,67 $
Last Close Price 81,27 $
Spread / Highest target 41,2%
Spread / Average Target 20,2%
Spread / Lowest Target -21,8%
EPS Revisions
Managers
NameTitle
Rice Powell Chairman-Management Board
Dieter Schenk Chairman-Supervisory Board
Helen Giza Chief Financial Officer
Olaf Schermeier CEO-Global Research & Development
Franklin W. Maddux Global Chief Medical Officer
Sector and Competitors